



23 February 2022

## Economic and Fixed Income research

### February 2022 Budget Review: Thanks to “windfall” revenues, debt ship has not quite sailed

#### Key takeaways

The Minister of Finance divided the windfall revenue receipts of F21/22 between deficit reduction and spending priorities. This meets our criteria of our Budget Preview titled “Spending the windfall wisely”.

Key issues we were watching were mostly in line with our expectations:

- Macro economic forecasts over the MTEF period remains lacklustre, with 2.1%, 1.6% and 1.7% projected for 2022, 2023 and 2024.
- The size of the revenue overrun in FY21/22 relative to the November 2022 MTBPS is projected to be R66bn (ICIB forecast: R45bn). Base effects and a higher tax buoyancy forecast raise F22/23s revenue forecast by R70bn (ICIB forecast: R50bn).
- Expenditure is forecast to increase by R78bn in FY22/23 (ICIBs forecast: R40bn). The FY21/22 main budget deficit has been revised down to 5.5% of GDP (in line with ICIBs forecast) compared to the MTBPS forecast of 6.6% of GDP. The forecast for F22/23 is unchanged at 6.6% of GDP, in line with our expectations.
- Fiscal consolidation over the MTEF period is helped by a moderation in bond supply, a drawdown of sterilisation deposit and an increase in the nominal GDP growth rate. Of interest is that a primary budget surplus is expected as soon as F24/25. We view this as ambitious given the risks to revenue and expenditure forecasts.
- Bond supply in F22/23 is forecast to rise from R285bn to R330bn. Issuance will consist of SAGBs, ILBs, rand-denominated Sukuk bonds and a new FRN. We expect the quantum of the weekly bond auctions to remain unchanged while awaiting more details on the FRN in coming months. Switch auctions of the R2023 of R5bn will continue. Net T-bill issuance is expected to be flat in F22/23 following a net decline of R6.8bn in F21/22. A drawdown of the sterilisation deposit of R41bn is a contributory factor. The extent to which bond supply could be raised is a function of a FRN issuance, which the Budget Review has not elaborated on.
- No additional assistance has been provided to SOE's.

Risks to the MTEF forecast:

- A slower growth recovery as National Treasury's GDP forecasts factors in firmer commodity prices and Chinese growth, which supports its tax buoyancy and revenue projection.
- Limited progress has been made on SOE reforms although SONA noted that some of the SOE's could be disposed of.
- The public sector wage bill with the gratuity bonus of R20.4bn carried over into F22/23 with wage negotiations starting in March 2022. In our view, the latter should form part of President Ramaphosa's 100 day target to reach a comprehensive social compact, focused on strengthening the ERRP which requires trade offs between stakeholders in the economy.

**Bond market outlook:** We view the Budget Review 2022 as neutral for the country risk premium and the rand.

**Tertia Jacobs**  
+27 11 286 8659  
tertia.jacobs@investec.co.za

## Main points

### Debt stabilisation

A key focus of the February 2022 Budget Review has been the allocation of the revenue overrun in stabilising the rising debt trajectory. Positive progress has been made and a debt trap, which featured prominently in 2020, has been avoided. The allocation of the revenue windfall to reduce debt issuance, has been amplified by two important developments in 2020: (1) an 11% increase in the size of the economy and (2) a wage freeze, which lowered spending by R37bn. The ruling by the Constitutional Court on the latter remains an outstanding and is viewed as a risk to the forecast.

Progress is made in reducing the primary balance deficit from 1.35% of GDP in FY21/22 to zero by FY23/24. A surplus is envisaged as early as FY24/25, which we deem as ambitious, considering the risks to the forecast. Additionally, the debt servicing forecast in absolute terms, have not been adjusted from the MTBPS projection to reflect the lower gross debt forecast. National Treasury expects the debt to GDP ratio to peak at 75.1% of GDP in F24/25 (MTBPS forecast: 77.8% of GDP). However, risks to the expenditure forecast remains elevated and the credibility attached to the debt to GDP forecast, remains low.

The macro economic assumptions factored into the fiscal forecasts are reasonable but more optimistic than ICIB's forecast. Real GDP growth in 2022 is expected at 2.1% (ICIB at 1.8%) and CPI inflation has been revised to 4.8% from 4.2% (ICIB F: 5.4%). The nominal GDP growth forecasts are revised up to 12.3% (10.3%), 3.0% (2.9%) and 5.7% (5.5%) for F21/22, F22/23 and F23/24, which assumes a stronger terms of trade in 2022. This supports an upward revision to revenue receipts of 2.5% (previously 4.2%). The real GDP forecast factors in a modest acceleration in fixed investment but not sufficient to provide a lift to the growth forecast of 1.6% and 1.7% in 2023 and 2024. The incremental nature of the economic reform process and a slow rollout of infrastructure projects remains a major constraint to accelerating growth momentum in the context of the potential GDP growth rate at ~1%, owing to the electricity constraint. Shovel-ready projects are few, with the development of a pipeline of projects held back by capacity and coordination constraints in all spheres of government. President Ramaphosa announced a number of initiatives to overcome obstacles to growth in the February 2022 SONA.


### Alleviating the tax burden on households and corporates

The overrun in revenue receipts allows for some support to disposable incomes. Allowance has been made for bracket creep of R13.2bn (compared to R2bn in F21/22) based on an inflation increase of 4.5%, by raising tax brackets. The fuel and RAF levies have been left unchanged, while another steep increase in the fuel price of ~R1.30/l is expected in March. Excise duties on alcohol will be raised by between 4.5% to 6.5% and tobacco by 5.5% to 6.5%. The carbon levy will be increased by 1c to 9c/l for petrol and 10c/l for diesel.

The focus in the SONA of enabling the private sector by an improvement in infrastructure, has been enhanced by a reduction in the corporate income tax rate from 28% to 27% for companies with financial year ending in F22/23. However, the effect on the fiscus is expected to be neutral as the tax base is set to be widened by measures such as restricting assessed losses and additional interest limitations.


SARS remains critical to widening the tax base in South Africa and close a tax gap, estimated at R200bn. We note that 490 new personnel has been appointed in the the past year.

**Figure 1: Main budget deficit as % of GDP – Improvement but MTEF risks remain**




Source: National Treasury, ICIB

**Figure 2: Breakdown of the main budget deficit: Primary balance and interest payments (% of GDP)**




Source: National Treasury, ICIB

**Figure 3: Debt servicing costs as % of GDP remains high**



Source: National Treasury, ICIB

**Figure 4: Moderation in gross debt to GDP trajectory**



Source: National Treasury, ICIB

**“Wise” allocation of expenditure**

Additional allocations of R78bn have been made for F22/23. This consisted of the SDR grant (R45bn), Sasria (R7.5bn) and the President Employment initiative of R20.4bn. While the Minister of Finance stated that the increase in the SDR is temporary, the MTEF period maintains an unallocated reserve of R25bn and R30bn in F23/24 and F24/25. This covers downside risk to revenue receipts and/or an increase in a permanent income transfer, which is widely anticipated. National Treasury against stressed a permanent increase needs to be financed from a permanent income. In this respect, R50bn can be generated by a 2ppt increase in the VAT rate or a 2pp increase in all marginal personal income tax rates.

The increase in the compensation bill in F22/22 consist of a carryover of the gratuity bonus of R20.4bn, as presented in the November 2022 MTBPS. Wage negotiations start in March 2022.

Risks to the forecast over the MTEF period remains unforeseen liquidity injections to SOEs, the growth recovery and the revenue forecast.

### SOEs support remains unresolved with elevated risks

Contingent liabilities have increased in F21/22. Exposure to SOEs increased from R384.7bn to R416.8bn, consisting mainly to more guarantees issued to Eskom (rising from R298.3bn to R327.9bn) and Sanral (from R37.4bn to R49.1bn). Guarantees to SAA declined from R6.7bn to R2.9bn and TCTA from R13.2bn to R9.5bn. The President stated in the SONA that government will adopt a centralised shareholder model for its key commercial state-owned companies. The Presidential SOE Council is preparing recommendations on SOEs to be retained, consolidated or disposable of. With limited progress and reforms in 2021, this remains a crucial area of uncertainty for the fiscus and the government's contingent liabilities.

**Figure 5: Gross borrowing requirement and funding**

R billion	2021/22		2022/23		2024/25	2024/25
	MTBPS	ICIB F	Feb 22	ICIB	Feb 22	Feb 22
<b>Gross borrowing</b>						
<b>Main budget balance</b>	<b>-346.9</b>	<b>-349.9</b>	<b>-387.2</b>	<b>-380.4</b>	<b>-331.2</b>	<b>-322.4</b>
<b>Redemptions</b>	<b>-65.6</b>	<b>-65.2</b>	<b>-97.2</b>	<b>-90.7</b>	<b>-155.8</b>	<b>-156.9</b>
Domestic long-term loans	-61.3	-61.3	-81.3	-75.0	-113.1	-121.2
Foreign loans	-3.9	-3.9	-16.0	-15.7	-42.0	-35.8
<b>Total</b>	<b>-412.0</b>	<b>-415.1</b>	<b>-484.5</b>	<b>-471.1</b>	<b>-4887.6</b>	<b>-479.3</b>
<b>Financing</b>						
Domestic short-term loans (net)	-6.8	0	0	45.0	40.0	39.0
Domestic long-term loans	285.3	280.0	330.0	300.0	360.0	353.2
Foreign loans	80.6	77.6	47.9	47.0	65.3	66.8
Change in cash and other balances	52.9	57.5	106.2*	79.0	22.0	20.3
<b>Total</b>	<b>412.0</b>	<b>415.1</b>	<b>493.3</b>	<b>471.0</b>	<b>487.6</b>	<b>479.3</b>

\*Rundown in sterilisation deposit of R41bn  
National Treasury, ICIB

### Financing strategy

- The main budget deficit in FY21/22 has been reduced from R482.6bn to R346.9bn. The MTBPS projected a zero increase in net T-bill issuance but lower demand for T-bills is expected to lead to a net decline of R6.8bn. Cash raised from long-term loans is unchanged at R285bn while a rundown in cash balances reduces the cash balance from R112.6bn to R52.9bn. The budget includes \$3bn to be raised on the international capital markets by 31 March 2022.
- In F22/23, the gross borrowing requirement is estimated to amount to R484.7bn. This consists of a main budget deficit of R387.2bn and bond redemptions of R97.2bn. The outstanding amount of R2023s of R81.3bn is expected to be reduced as switch auctions will continue in 2022.
- The funding mix consists of the following:
  - Net T-bill issuance is expected to be zero, with an increase replaced by a drawdown of the sterilisation deposit of R41bn.
  - Long term bond issuance is forecast to be raised from R285bn in FY21/22 to R330bn in FY22/23. The funding instruments will consist of SAGBs and ILBs, in addition to a new FRN and a rand-denominated Sukuk bond. The current funding pace of SAGBs and ILBs amounts to ~R280bn, with the swing factor the take up of weekly non-competitive auctions. For the quantum of bond auctions to remain unchanged, a FRN of ~R50bn is required. This in turn will depend on the size of a

rand-Sukuk issue. More details of a FRN and quantum of weekly bond auctions are expected in the coming months.

- The funding strategy over the MTEF includes a total of \$11bn of funds to be raised in the international capital market and from DFIs.

## Contact details

### Institutional Sales and Structuring, Investec Specialist Bank

[InstitutionalSales&Structuring@investec.co.za](mailto:InstitutionalSales&Structuring@investec.co.za)

#### Distribution and Syndication

[Leanne Large](#) +27 21 416 3303

[Keshiv Navagar](#) +27 11 286 8715

#### Long Term and Structuring

[Firdaus Aziz](#) +27 11 263 5144

#### Institutional Sales and Structuring

[Laurence Adams](#) +27 21 416 3351

[Freda Hamersma](#) +27 21 809 0717

#### Money Market

[Jeanine Polley](#) +27 11 286 4824

[Lettie Matthews](#) +27 11 286 4825

[Ruanita de Kock](#) +27 11 286 9815

### Insto Sales

[insto.sales@investec.co.za](mailto:insto.sales@investec.co.za)

#### Fixed Income Economist / Strategist

[Tertia Jacobs](#) +27 11 286 8659

#### Interest Rate Derivatives

[Denvin Naidoo](#) +27 11 286 4671

#### FX Trading

[Thulane Kunene](#) +27 11 286 4810

#### Bond Trading

[Steven Arnold](#) +27 11 286 4720

### Third party research disclosures

This report has been produced by a non-member affiliate of Investec Securities (US) LLC and is being distributed as third-party research by Investec Securities (US) LLC in the United States. In the United States, this report is not intended for use by or distribution to entities that do not meet the definition of a Major US Institutional Investor, as defined under SEC Rule 15a-6, or an Institutional Investor, as defined under FINRA rule 4512 (c), or for use by or distribution to any individuals who are citizens or residents of the United States. Investec Securities (US) LLC accepts responsibility for the issuance of this report when distributed in the United States to entities who meet the definition of a US Major Institutional Investor or an Institutional Investor.

### SEC Regulation Best Interest

If you are a United States "retail investor," as defined by the Securities and Exchange Commission ("SEC") Regulation Best Interest, please click here to download SEC Form CRS for important information before you invest.

### Managing conflicts

Investec Securities (Investec) has investment banking relationships with a number of companies covered by our Research department. In addition we may seek an investment banking relationship with companies referred to in this research. As a result investors should be aware that the firm may have a conflict of interest which could be considered to have the potential to affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

### Investec Securities:

In the United Kingdom refers to Investec Securities a division of Investec Bank plc.

Investec Bank plc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

Registered in England No. 489604

**Registered Office Address:**  
30 Gresham Street London EC2V 7QP

In South Africa refers to:

Investec Bank Limited an authorised financial services provider and a member of the JSE Limited.

Registered in South Africa No. 1969/004763/06

Investec Markets (Pty) Limited a member of JSE Limited.

Registered in South Africa No. 2018/243092/07

**Registered Office Address:**

100 Grayston Drive  
Sandown, Sandton  
2196, South Africa

In Australia refers to Investec Securities a division of Investec Australia Limited.

Investec Australia Limited is authorised and regulated by the Australian Securities & Investments Commission (Licence Number 342737, ABN 77 140 381 184)

**Registered Office Address:**

Level 23, Chifley Tower  
2 Chifley Square  
Sydney, NSW 2000

In Hong Kong refers to Investec Capital Asia Limited a Securities and Futures Commission licensed corporation (Central Entity Number AFT069).

**Registered Office Address:**

Suites 3901-08, 39/F, Jardine House  
1 Connaught Place, Central, Hong Kong

In India refers to Investec Capital Services (India) Private Limited which is registered with the Securities and Exchange Board of India, the Capital Market regulator in India as a research analyst, Registration number INH000000263.

**Registered Office Address:**

Investec Capital Services ( India ) Private Limited  
Parinee Crescenzo, C 38 & 39, "G" Block,  
11th flr , B Wing , Unit No 1103 & 1104  
Bandra Kurla Complex, Mumbai - 400 051, India

In Singapore refers to Investec Singapore Pte. Ltd. an exempt financial adviser which is regulated by the Monetary Authority of Singapore as a capital markets services licence holder.

Registration No. 201634931E

**Registered Office Address:**

80 Raffles Place  
#36-09, UOB Plaza  
Singapore 048624

In the United States refers to Investec Securities (US) LLC.

**Registered Office Address:**

10 East 53rd Street, 22nd Floor  
New York, NY 10022

Further details of Investec office locations, including postal addresses and telephone/fax contact details: [https://www.investec.com/en\\_gb/welcome-to-investec/contact-us.html](https://www.investec.com/en_gb/welcome-to-investec/contact-us.html)

## Important Disclaimer – please read

For the purposes of this disclaimer, "Investec Securities" shall mean: (i) Investec Bank plc ("IBP"); (ii) Investec Bank Limited ("IBL"); (iii) Investec Markets (Pty) Limited ("IML"); (iv) Investec Australia Limited ("IAL"); (v) Investec Capital Asia Limited ("ICAL"), (vi) Investec Capital Services (India) Private Limited and (vii) Investec Singapore Pte. Ltd ("ISPL") and from time to time, in relation to any of the foregoing entities, the ultimate holding company of that entity, a subsidiary (or a subsidiary of a subsidiary) of that entity, a holding company of that entity or any other subsidiary of that holding company, and any affiliated entity of any such entities. "Investec Affiliates" shall mean any directors, officers, representatives, employees, advisers or agents of any part of Investec Securities. This research report has been issued solely for general information and should not be considered as an offer or solicitation of an offer to sell, buy or subscribe to any securities or any derivative instrument or any other rights pertaining thereto.

This research may have been issued to you by one entity within Investec Securities in the fulfilment of another Investec Securities entity's agreement to do so. In doing so, the entity providing the research is in no way acting as agent of the entity with whom you have any such agreement and in no way is standing as principal or a party to that arrangement. The information in this report has been compiled by Investec Securities from sources believed to be reliable, but neither Investec Securities nor any Investec Affiliates accept liability for any loss arising from the use hereof or makes any representations as to its accuracy and completeness. Any opinions, forecasts or estimates herein constitute a judgement as at the date of this report. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance. The information in this research report and the report itself is subject to change without notice.

This research report as well as any other related documents or information may be incomplete, condensed and/or may not contain all material information concerning the subject of the research and/or its group companies (including subsidiaries); its accuracy cannot be guaranteed. Investec Securities has no obligation to update, modify or amend this research report or to otherwise notify a recipient thereof if an opinion, forecast or estimate changes or becomes inaccurate. Coverage and the frequency of changes in market conditions and in both general and company-specific economic prospects make it difficult to update research at defined intervals. Updates are at the sole discretion of the analyst or the Head of Research and reports may be published at irregular intervals. Investec Securities (or its directors, officers or employees) may, to the extent permitted by law, own or have a position in the securities or financial instruments (including derivative instruments or any other rights pertaining thereto) of any company or related company referred to herein, and may add to or dispose of any such position or may make a market or act as a principal in any transaction in such securities or financial instruments. Directors of Investec Securities may also be directors of any of the companies mentioned in this report. Investec Securities may from time to time provide or solicit investment banking, underwriting or other financial services to, for or from any company referred to herein. Investec Securities (or its directors, officers or employees) may, to the extent permitted by law, act upon or use the information or opinions presented herein, or research or analysis on which they are based prior to the material being published. Investec Securities may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them. The value of any securities or financial instruments mentioned in this report can fall as well as rise. Foreign currency denominated securities and financial instruments are subject to fluctuations in exchange rates that may have a positive or adverse effect on the value, price or income of such securities or financial instruments. Certain transactions, including those involving futures, options and other derivative instruments, can give rise to substantial risk and are not suitable for all investors. This report does not contain advice, except as defined by the *Corporations Act 2001* (Australia). Specifically, it does not take into account the objectives, financial situation or needs of any particular person. Investors should not do anything or forebear to do anything on the basis of this report. Before entering into any arrangement or transaction, investors must consider whether it is appropriate to do so based on their personal objectives, financial situation and needs and seek financial advice where needed.

No representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability is or will be accepted by Investec Securities or any Investec Affiliates as to, or in relation to, the accuracy, reliability, or completeness of the contents of this research report and each entity within Investec Securities (for itself and on behalf of all Investec Affiliates) hereby expressly disclaims any and all responsibility or liability for the accuracy, reliability and completeness of such information or this research report generally.

The securities or financial instruments described herein may not have been registered under the US Securities Act of 1933, and may not be offered or sold in the United States of America or to US persons unless they have been registered under such Act, or except in compliance with an exemption from the registration requirements of such Act. US entities that are interested in trading securities listed in this report should contact a US registered broker dealer.

This report and the distribution of this report do not constitute an offer or an invitation to offer to the Hong Kong or Singaporean public to acquire, dispose of, subscribe for or underwrite any securities or related financial instruments. Neither this research report nor the information contained in it is intended to be an offer to any person, or to induce or attempt to induce any person to enter into or to offer to enter into any agreement for or with a view to acquiring, disposing of, subscribing for or underwriting securities. The distribution of this document in other jurisdictions may be prohibited by rules, regulations and/or laws of such jurisdiction. Any failure to comply with such restrictions may constitute a violation of United States securities laws or the laws of any such other jurisdiction.

For readers of this report in: **South Africa:** this report is produced by IBL an authorised financial services provider and a member of the JSE Limited. **United Kingdom and Europe:** this report is produced by IBP and was prepared by the analyst named in this report. IBP is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. This report may only be issued to professional clients, eligible counterparties and investment professionals, as described in S19 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 and is not intended for retail clients. **Australia:** this report is issued by IAL holder of Australian Financial Services License No. 342737 only to 'Wholesale Clients' as defined by S761G of the Corporations Act 2001. **Hong Kong:** this report is distributed in Hong Kong by ICAL, a Securities and Futures Commission licensed corporation (Central Entity Number AFT069) and is intended for distribution to professional investors (as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) only. This report is personal to the recipient and any unauthorised use, redistribution, retransmission or reprinting of this report (whether by digital, mechanical or other means) is strictly prohibited. **India:** this report is issued by Investec Capital Services (India) Private Limited which is registered with the Securities and Exchange Board of India. **Singapore:** This report is produced by IBP and issued and distributed in Singapore through Investec Singapore Pte. Ltd., an exempt financial adviser which is regulated by the Monetary Authority of Singapore as a capital markets services licence holder. This material is intended only for, and may be issued and distributed in Singapore only to accredited investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 ("SFA"). This material is not intended to be issued or distributed to any retail or other investors. ISPL may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Singapore recipients of this document should contact ISPL at the above address in respect of any matters arising from, or in connection with, this report. **Canada:** this report is issued by IBP, and may only be issued to persons in Canada who are able to be categorised as a "permitted client" under National Instrument 31-103 Registration Requirements and Exemptions or to any other person to whom this report may be lawfully directed. This report may not be relied upon by any person other than the intended recipient.

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of an entity within Investec Securities. Securities referred to in this research report may not be eligible for sale in those jurisdictions where an entity within Investec Securities is not authorised or permitted by local law to do so. In the event that you contact any representative of Investec Securities in connection with receipt of this research, including any analyst, you should be advised that this disclaimer applies to any conversation or correspondence that occurs as a result, which is also engaged in by Investec Securities and any relevant Investec Affiliate solely for the purposes of providing general information only. Any subsequent business you choose to transact shall be subject to the relevant terms thereof. We may monitor e-mail traffic data and the content of email. Calls may be monitored and recorded. Investec Securities does not allow the redistribution of this report to non-professional investors or persons outside the jurisdictions referred to above and Investec Securities cannot be held responsible in any way for third parties who effect such redistribution or recipients thereof. © 2020